UpdatesPress Release
Jagsonpal Pharma reported strong Q1 FY27: Revenue +9%, PAT +22%, Op.
Jagsonpal Pharmaceuticals LimitedJAGSNPHARM · Filed with the exchange
EBITDA +21%. It acquired 85% of Aequitas Healthcare for ₹20.8 Cr, entering hospital supplies and targeting ₹10 Cr EBITDA post-integration.
Cash reserves remain robust at ₹170 Cr despite a ₹40 Cr share buyback.
No comments yet. Be the first.